Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Restructuring Positions Leichleiter As Heir Apparent To CEO Taurel

Executive Summary

Lilly's promotion of John Leichleiter to president and chief operating officer positions him as the likely successor to CEO Sidney Taurel
Advertisement

Related Content

Lilly restructuring (correction)
Lilly restructuring (correction)
Zyprexa Patent Valid: Lilly’s Phase I Olanzapine Trials Were Not “Public Use”
Big Pharma “Cost Structure” Needs Attention, Lilly CEO Says
Lilly Expects Full GMP Inspection After Upgrades To “Building 105”
Lilly CEO-Designate Taurel Will Guide Company To Post-Prozac Future
Lilly CEO-Designate Taurel Will Guide Company To Post-Prozac Future

Topics

Advertisement
UsernamePublicRestriction

Register

PS046360

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel